)
)
)
Alphyn Biologics, Inc.
Company Description: Alphyn Biologics, Inc. is advancing breakthrough therapies for skin diseases using its patented drug platform for first-in-class Multi-Target Therapeutics®. The company's platform technology is an innovation that has multiple bioactive compounds, with multiple mechanisms of action, to uniquely target the interconnected causes of dermatologic diseases. Alphyn's lead drug candidate for atopic dermatitis has completed Phase 2 trials with superior results, positioning to be the first drug to directly target AD’s four key problems – itch, inflammation, bacteria, and dry skin. Our second drug candidate for molluscum contagiosum virus directly treats the multiple disease problems of the virus, itch, inflammation and, in certain patients, dermatitis and bacterial infection with its associated pain. Alphyn’s platform drug candidates have a robust safety, side effect, and patient tolerability profile, supporting worry-free, long-term use. They have broad patent protection through 2043.
Goal for Presentation: Raising Series C and securing strategic partners
Additional Comments:
Who referred you to this application?:
Goal for Presentation: Raising Series C and securing strategic partners
Additional Comments:
Who referred you to this application?:
What is your next catalyst (value inflection) update?
Phase 2b results of Zabalafin Hydrogel for Atopic Dermatitis; Phase 2 results for Zabalafin for Molluscum Contagiosum
Year Founded
2020 - operational
Lead Product in Development
Zabalafin Hydrogel for Atopic Dermatitis
Zabalafin Hydrogel (ZH), is a topical therapeutic for atopic dermatitis (AD). Zabalafin Hydrogel is unique with multiple bioactive compounds to treat the multiple problems of AD. It's the only therapeutic among commercialized and investigational drugs to directly treat all of AD's interconnected problems - itch, inflammation, bacteria, and dry skin. Phase 2a clinical results demonstrated superiority to commercial and investigational AD drugs, along with a better safety and patient tolerability profile, positioning it to be the drug of choice for long-term, worry-free use. Phase 2b clinical trials are underway, with results expected in mid-2026.
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
Two
CEO/Top Company Official
Neal Koller, CEO
When you expect your next catalyst update?
June 2026 for atopic dermatitis; July/August 2026 for molluscum contagiosum virus
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
